logo
logo

Giiant Pharma Inc Announced The Closing Of Us$11M In Seed Financing To Develop Its Precision Delivery Technology Platform In Gastroenterology

May 21, 2021•about 4 years ago

Round Type

seed

Montreal

Description

Giiant Pharma inc., a Montreal-based preclinical-stage biotech company, today announced the closing of US$11M (CAD$ 13.5M) million in Seed financing. The round was co-led by Amplitude Ventures and Genesys Capital, with participation from Fonds de solidarité FTQ, AmorChem II Fund, Theodorus Investment Funds, Anges Québec, and other angel investors.

Company Information

Company

Giiant Pharma Inc

Location

Montreal, Quebec, Canada

About

Giiant is a preclinical-stage biotech company, with its proprietary Precision Delivery technology platform, designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology. Its lead program GT-2108 is a microbiota-activated PDE4 inhibitor prodrugs, with improved drug tolerability and enhanced therapeutic effect.